Comparative Pharmacology
Head-to-head clinical analysis: CYCLESSA versus MIUDELLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLESSA versus MIUDELLA.
CYCLESSA vs MIUDELLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of estrogen (ethinyl estradiol) and progestin (desogestrel) inhibits ovulation by suppressing gonadotropin release, increases viscosity of cervical mucus to impede sperm penetration, and alters endometrial receptivity.
MIUDELLA (everolimus) is an mTOR inhibitor that binds to the FKBP-12 protein to form a complex that inhibits the mTOR kinase activity, thereby reducing cell proliferation, angiogenesis, and glucose uptake.
One tablet (0.15 mg desogestrel/0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Intravenous: 1.5 mg/kg every 12 hours for 14 days.
None Documented
None Documented
Desogestrel: 38±13 hours (terminal); ethinyl estradiol: 14±3 hours (terminal). Steady-state reached after 7-10 days.
Terminal elimination half-life is 18-24 hours in healthy adults; prolonged in renal impairment (up to 40 hours in severe cases).
Urine (50-60% as metabolites, <10% unchanged); feces (30-40% as metabolites); enterohepatic circulation.
Primarily renal excretion of unchanged drug (85-90%); biliary/fecal elimination accounts for 5-10%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive